Experimental immunotherapy combo for tough colorectal cancer trial pulled before start
NCT ID NCT06557278
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study was designed to test an experimental immunotherapy called AlloStim combined with a checkpoint inhibitor (avelumab) in people with advanced colorectal cancer that had stopped responding to multiple prior treatments. The trial was withdrawn before any participants were enrolled, so no data on safety or effectiveness were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AlloStim (experimental immunotherapy) plus avelumab (anti-PDL1 checkpoint inhibitor)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced colorectal cancer that hasn't responded to other therapies.
What could go wrong
This trial was withdrawn before enrolling any participants, so no results are available. The combination is experimental and early-stage, with unknown safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hirschfield Oncology Center
Brooklyn, New York, 11206, United States
-
Mt. Sinai Comprehensive Cancer Center
Miami Beach, Florida, 33140, United States
-
New York Cancer and Blood Specialists
Shirley, New York, 11967, United States